Mutations of the BRAF gene in human cancer
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Cancers arise owing to the accumulation of mutations in critical genes that alter normal programmes of cell proliferation, differentiation and death. As the first stage of a systematic genome-wide screen for these genes, we have prioritized for analysis signalling pathways in which at least one gene is mutated in human cancer. The RAS RAF MEK ERK MAP kinase pathway mediates cellular responses to growth signals. RAS is mutated to an oncogenic form in about 15% of human cancer. The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS. Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers. All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%. Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells. Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation. As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The hotspot BRAF V600E mutation at codon 600 of exon 15 increases the activity of BRAF kinase by 130- to 700-fold [26, 93–95].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [95]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAFV600E mutations occur in ∼10% of colorectal cancer (CRC) patients, leading to poor prognosis.”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAFV600E mutations are present in around 10% of advanced CRC patients and lead to constitutive activation of the MAPK pathway, drug resistance and a poor prognosis [1–4].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BRAF mutations occur in roughly 5–15% of CRCs (1–3, 17)”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [17]
In the citing paper
“Among patients with colorectal cancer, there is an approximately 10% incidence of BRAF mutation [36].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [36]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“There has recently been marked success reported of an inhibitor (STI571) of the BCR-ABL kinase in the treatment of chronic myeloid leukaemi”
BackgroundIdentification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015 · cited 1×
“To evaluate whether activating mutations of BRAF signal through MEK and ERK, we treated cells with the MEK1/2 inhibitor U0126 (ref”
MethodMeaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
Kölch, W. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510289 · Cited by 1,441 · cited 1×
“The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RA”
BackgroundRequirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells
Mulcahy, L. S., Smith, M. R., & Stacey, D. W. (1985) · Nature · doi:10.1038/313241a0 · Cited by 878 · cited 1×
“Studies using injection of the RAS-neutralizing Y13-259 monoclonal antibody have previously shown that most normal cells examined and some tumour cells require RAS function for proliferation in cultur”
MethodThe Raf/MEK/ERK pathway: new concepts of activation
Peyssonnaux, C., & Eychène, A. (2001) · Biology of the Cell · doi:10.1016/s0248-4900(01)01125-x · Cited by 735 · cited 1×
“The RAS–RAF–MEK–ERK–MAP kinase pathway mediates cellular responses to growth signal”
BackgroundIncreasing Complexity of the Ras Signaling Pathway
Vojtek, A. B., & Der, C. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.19925 · Cited by 579
Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation
Mason, C. S. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2137 · Cited by 457 · cited 1×
“Myc-epitope-tagged versions of complementary DNAs containing these mutations were transiently expressed in COS cells, immunoprecipitated using the Myc-tag and examined in a kinase cascade assay using bacterially produced glutathione S -transferase (GST)–MEK, GST–ERK and myelin basic protein (MBP) as sequential substra…”
MethodSelf-citationDifferential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456 · cited 1×
“Myc-epitope-tagged versions of complementary DNAs containing these mutations were transiently expressed in COS cells, immunoprecipitated using the Myc-tag and examined in a kinase cascade assay using bacterially produced glutathione S -transferase (GST)–MEK, GST–ERK and myelin basic protein (MBP) as sequential substra…”
MethodSelf-citationRas Activation of the Raf Kinase: Tyrosine Kinase Recruitment of the MAP Kinase Cascade
Avruch, J. (2001) · Recent Progress in Hormone Research · doi:10.1210/rp.56.1.127 · Cited by 391 · cited 1×
“The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RA”
Background
Cited by
Items 1,001–1,100 of 1,150
Vaqué, J. P., Dorsam, R. T., Feng, X., Iglesias-Bartolome, R., Forsthoefel, D. J., Chen, Q., Debant, A., Seeger, M. A., Ksander, B. R., Teramoto, H., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.10.018 · Cited by 162
“These mutated forms, collectively known as the GNAQ oncogene, result in the activation of ERK in the absence of mutations in the B-RAF or N-RAS oncogenes, which are frequently mutated in cutaneous melanomas (Davies et al., 2002).”
Somatic alterations in the human cancer genome
Weir, B., Zhao, X., & Meyerson, M. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.11.004 · Cited by 166
Melanoma: New Insights and New Therapies
Nikolaou, V. A., Stratigos, A. J., Flaherty, K. T., & Tsao, H. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.421 · Cited by 163
“Approximately 60% of all melanomas harbor activating mutations in BRAF, making this gene a prime therapeutic target (Davies et al., 2002).”
BackgroundInfluentialPotential therapeutic targets of epithelial–mesenchymal transition in melanoma
Pearlman, R. L., Montes de Oca, M. K., Pal, H. C., & Afaq, F. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.029 · Cited by 165
MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation
Chadee, D. N., & Kyriakis, J. M. (2004) · Nature Cell Biology · doi:10.1038/ncb1152 · Cited by 163
“Mutant GTPase-deficient ras alleles occur in up to 30% of cancers, and activating mutations in B-raf , which encodes a Ras effector, are prevalent in malignant melanoma and colorectal cancer”
BackgroundMITF and UV responses in skin: From pigmentation to addiction
Nguyen, N. T., & Fisher, D. E. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12726 · Cited by 161
“There is some controversy over the question of whether UVR induces the common valine- to- glutamic acid substitution at codon 600 (V600E) of BRAF within the MAPK pathway, which is the most commonly mutated oncogene, identified in 40%–60% of melanoma patients (Davies et al., 2002).”
BackgroundTuononen, K., Mäki‐Nevala, S., Sarhadi, V. K., Wirtanen, A., Rönty, M., Salmenkivi, K., Andrews, J. M., Telaranta‐Keerie, A. I., Hannula, S., Lagström, S., et al. (2013) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22047 · Cited by 160
Hamatani, K., Eguchi, H., Ito, R., Mukai, M., Takahashi, K., Taga, M., Imai, K., Cologne, J., Soda, M., Arihiro, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0293 · Cited by 160
“BRAF somatic mutations were first discovered in several types of human cancers, including malignant melanomas (24).”
BackgroundBRAF Mutations in Canine Cancers
Mochizuki, H., Kennedy, K., Shapiro, S. G., & Breen, M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0129534 · Cited by 159
“Constitutive activation of MAPK signaling by activating mutations of BRAF (~60%) or NRAS (~15%) genes plays an important role in the pathogenesis of human melanoma [4,5,11,12].”
BackgroundTolcher, A. W., Patnaik, A., Papadopoulos, K. P., Rasco, D. W., Becerra, C. R., Allred, A. J., Orford, K., Aktan, G., Ferron-Brady, G., Ibrahim, N., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2615-5 · Cited by 158
“In addition, activating BRAF mutations have been identified at a high frequency in melanoma (30–60 %), thyroid cancer (30–50 %), colorectal cancer (5–20 %), and ovarian cancer (~30 %) [5, 6].”
BackgroundTbx3 Represses E-Cadherin Expression and Enhances Melanoma Invasiveness
Rodriguez, M., Aladowicz, E., Lanfrancone, L., & Goding, C. R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0301 · Cited by 157
“The genetic model of malignant melanoma progression (1) suggests that melanoma initiates with the acquisition by melanocytes or their stem cells of a proliferative phenotype, usually by a gain of function of BRAF or NRAS kinases (2), combined with a suppression of stress or aberrant signaling-induced senescence (3–5).”
BackgroundMethodInfluentialClinicopathological relevance of BRAF mutations in human cancer
Pakneshan, S., Salajegheh, A., Anthony Smith, R., & King-Yin Lam, A. (2013) · Pathology · doi:10.1097/pat.0b013e328360b61d · Cited by 156
“BRAF mutations are found in 1–3% of non-small cell lung carcinomas, most of which are adenocarcinoma.(91,92) The mutations are mutually exclusive with the other common driver”
BackgroundOrgaz, J. L., Crosas-Molist, E., Sadok, A., Perdrix-Rosell, A., Maiques, O., Rodriguez-Hernandez, I., Monger, J., Mele, S., Georgouli, M., Bridgeman, V., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.003 · Cited by 151
“, 2014a)––in contrast with frequently mutated MAPK (Davies et al., 2002; Cancer Genome Atlas Network, 2015).”
BackgroundSenescence as a therapeutically relevant response to CDK4/6 inhibitors
Wagner, V., & Gil, J. (2020) · Oncogene · doi:10.1038/s41388-020-1354-9 · Cited by 148
UV-Induced Molecular Signaling Differences in Melanoma and Non-melanoma Skin Cancer
Liu-Smith, F., Jia, J., & Zheng, Y. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-56017-5_3 · Cited by 147
“Mutations in NRAS were found in 15–30% of melanomas and mutations in BRAF were found in ~60% of melanomas [45].”
BackgroundFriday, B. B., Yu, C., Dy, G. K., Smith, P. D., Wang, L., Thibodeau, S. N., & Adjei, A. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1430 · Cited by 146
“Although many BRAF mutations have been described, a single amino acid change, resulting in a valine to glutamic acid substitution at position 600 (V600E), accounts for f80% of the mutations (11).”
BackgroundMolecular Pathways and Mechanisms of BRAF in Cancer Therapy
Poulikakos, P. I., Sullivan, R. J., & Yaeger, R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2138 · Cited by 145
Carragher, L. A. S., Snell, K. R., Giblett, S. M., Aldridge, V. S. S., Patel, B., Cook, S. J., Winton, D. J., Marais, R., & Pritchard, C. A. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000099 · Cited by 144
“BRAF is a serine-threonine protein kinase component of the RAS/RAF/MEK/extracellular signal-regulated kinase (ERK) signalling pathway and is activated by somatic mutations, giving rise to gain of function in human cancers (Davies et al, 2002; Garnett & Marais, 2004; Mercer & Pritchard, 2003).”
Self-citationMolecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges
Shih, I.-M., & Kurman, R. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0755 · Cited by 142
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
Yen, I., Shanahan, F., Lee, J., Hong, Y. S., Shin, S. J., Moore, A. R., Sudhamsu, J., Chang, M. T., Bae, I., Dela Cruz, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03515-1 · Cited by 138
Gao, H., Ouyang, X., Banach-Petrosky, W. A., Gerald, W. L., Shen, M. M., & Abate-Shen, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606836103 · Cited by 141
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma
Corcoran, R. B., Rothenberg, S. M., Hata, A. N., Faber, A. C., Piris, A., Nazarian, R. M., Brown, R. D., Godfrey, J. T., Winokur, D., Walsh, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005753 · Cited by 140
Vella, L. J., Pasam, A., Dimopoulos, N., Andrews, M., Knights, A., Puaux, A.-L., Louahed, J., Chen, W., Woods, K., & Cebon, J. S. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0181 · Cited by 139
“Introduction As a result of the identification of mutations in the BRAF kinase as an oncogenic driver in cutaneous melanomas (1, 2), BRAFkinase inhibitors (BRAFi) have nowbecome the standard of care for treatment of patients with metastatic melanoma bearing V600 mutations (3).”
BackgroundBRAF Mutation in Colorectal Cancer: An Update: Supplementary Issue: Biomarkers for Colon Cancer
Barras, D. (2015) · Biomarkers in Cancer · doi:10.4137/bic.s25248 · Cited by 138
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136
Toon, C. W., Walsh, M. D., Chou, A., Capper, D., Clarkson, A., Sioson, L., Clarke, S., Mead, S., Walters, R. J., Clendenning, M., et al. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31828f233d · Cited by 136
“Total, n (%) 98 (7) 183 (13) 93 (7) 1029 (73) Sex, n (%) Female 57 (58) 136 (74) 53 (57) 468 (46) Male 41 (42) 47 (26) 40 (43) 561 (55) Anatomic site, n (%) Cecum 20 (20) 50 (28) 33 (36) 182 (18) Ascending colon 31 (32) 64 (36) 25 (27) 110 (11) Transverse colon 16 (16) 40 (23) 21 (23) 71 (7) Descending colon 9 (9) 5 (…”
Abdel-Malek, Z. A., Kadekaro, A. L., & Swope, V. B. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00679.x · Cited by 134
“Utilizing a-MSH analogs should increase cutaneous photoprotection in individuals with functional MC1R, and should reduce the risk for melanoma in individuals with mutations in melanoma genes other than MC1R, such as p16 or BRAF.”
BackgroundInfluentialYadav, V., Burke, T. F., Huber, L., Van Horn, R. D., Zhang, Y., Buchanan, S. G., Chan, E. M., Starling, J. J., Beckmann, R. P., & Peng, S.-B. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0257 · Cited by 132
“B-RAF is the most commonly mutated driver oncogene in melanoma, with activating mutations in codon 600 occurring in almost 50% of the patients (1, 2).”
BackgroundMorris, V., Overman, M. J., Jiang, Z.-Q., Garrett, C., Agarwal, S., Eng, C., Kee, B., Fogelman, D., Dasari, A., Wolff, R., et al. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.06.001 · Cited by 132
Vemurafenib resistance reprograms melanoma cells towards glutamine dependence
Hernandez-Davies, J. E., Tran, T. Q., Reid, M. A., Rosales, K. R., Lowman, X. H., Pan, M., Moriceau, G., Yang, Y., Wu, J., Lo, R. S., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0581-2 · Cited by 131
“Oncogenic mutations in the BRAF gene, encoding a serine threonine kinase that is an essential part of the RAS–RAF–MEK–ERK signaling cascade have been found in approximately 50–70% of metastatic melanoma [1, 3].”
BackgroundUpdate on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
Underwood, P. W., Ruff, S. M., & Pawlik, T. M. (2024) · Cells · doi:10.3390/cells13030245 · Cited by 130
“Among patients with colorectal cancer, there is an approximately 10% incidence of BRAF mutation [36].”
BackgroundAloia, A., Müllhaupt, D., Chabbert, C. D., Eberhart, T., Flückiger-Mangual, S., Vukolic, A., Eichhoff, O., Irmisch, A., Alexander, L. T., Scibona, E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0253 · Cited by 130
“Approximately 50% of patients with melanoma carry gain-offunction mutations in the BRAF gene (2).”
BackgroundJohnson, G. L., Stuhlmiller, T. J., Angus, S. P., Zawistowski, J. S., & Graves, L. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1081 · Cited by 129
“BRaf is mutated in approximately 50% of metastatic melanomas, 55% of advanced thyroid carcinomas and in a lower proportion of colorectal, ovarian, and lung carcinomas (7, 28-32).”
BackgroundCombination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
Yu, C., Liu, X., Yang, J., Zhang, M., Jin, H., Ma, X., & Shi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00990 · Cited by 126
“%) of patients with BRAFV600E mutation compared with chemotherapy (33).”
BackgroundInfluentialFusion genes and chromosome translocations in the common epithelial cancers
Edwards, P. A. (2010) · The Journal of Pathology · doi:10.1002/path.2632 · Cited by 126
Faber, A. C., Coffee, E. M., Costa, C., Dastur, A., Ebi, H., Hata, A. N., Yeo, A. T., Edelman, E. J., Song, Y., Tam, A. T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0315 · Cited by 124
Sforza, V., Martinelli, E., Ciardiello, F., Gambardella, V., Napolitano, S., Martini, G., della Corte, C., Cardone, C., Ferrara, M. L., Reginelli, A., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6345 · Cited by 123
Oddo, D., Sennott, E. M., Barault, L., Valtorta, E., Arena, S., Cassingena, A., Filiciotto, G., Marzolla, G., Elez, E., van Geel, R. M. J. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0396 · Cited by 121
“Activating mutations in the BRAF oncogene occur in approximately 7% of human malignancies, including 50-60% of melanomas and 5-8% of colorectal cancers (CRCs) (1).”
Li, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa026 · Cited by 119
“Among them, BRAF accounts for >90% of BRAF mutations, which refers to the T-to-A changing at nucleotide 1799 and a substitution of valine to glutamic acid [64].”
BackgroundThe genetics and biology of KRAS in lung cancer
Westcott, P. M. K., & To, M. D. (2013) · Chinese Journal of Cancer · doi:10.5732/cjc.012.10098 · Cited by 116
Oncogenic mutations as predictive factors in colorectal cancer
Lièvre, A., Blons, H., & Laurent-Puig, P. (2010) · Oncogene · doi:10.1038/onc.2010.89 · Cited by 117
“This mutation is associated with elevated kinase activity and is able to transform NIH3T3 cells (Davies et al., 2002).”
BackgroundA Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells*
Stuart, S. A., Houel, S., Lee, T., Wang, N., Old, W. M., & Ahn, N. G. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.047233 · Cited by 116
“The importance of identifying targets of B-RAF/MKK/ERK signaling on a global scale is magnified by the fact that this pathway is constitutively activated in a number of human cancers, most notably melanoma, colorectal cancer, thyroid cancer, and glioblastoma (5).”
BackgroundBai, X., Fisher, D. E., & Flaherty, K. T. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0204-6 · Cited by 107
An Oncogenic Role for ETV1 in Melanoma
Jané-Valbuena, J., Widlund, H. R., Perner, S., Johnson, L. A., Dibner, A. C., Lin, W. M., Baker, A. C., Nazarian, R. M., Vijayendran, K. G., Sellers, W. R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3092 · Cited by 115
“Chromosome 7q contains the BRAF oncogene, which commonly undergoes activating point mutations in melanoma (4).”
BackgroundShin, D., Lee, W., Lee, J. H., & Bang, D. (2019) · Science Advances · doi:10.1126/sciadv.aav2249 · Cited by 101
KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth
Riverso, M., Montagnani, V, & Stecca, B. (2017) · Oncogene · doi:10.1038/onc.2016.481 · Cited by 115
PTEN functions as a melanoma tumor suppressor by promoting host immune response
Dong, Y., Richards, J.-A., Gupta, R., Aung, P. P., Emley, A., Kluger, Y., Dogra, S. K., Mahalingam, M., & Wajapeyee, N. (2014) · Oncogene · doi:10.1038/onc.2013.409 · Cited by 113
The Melanocortin 1 Receptor and the UV Response of Human Melanocytes—A Shift in Paradigm†
Abdel‐Malek, Z. A., Knittel, J., Kadekaro, A. L., Swope, V. B., & Starner, R. (2008) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2008.00294.x · Cited by 111
The RhoGEF GEF-H1 is required for oncogenic RAS signaling via KSR-1
Cullis, J., Meiri, D., Sandi, M. J., Radulovich, N., Kent, O. A., Medrano, M., Mokady, D., Normand, J., Larose, J., Marcotte, R., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.025 · Cited by 100
“RAS engages diverse signaling pathways, including RAF, PI3K, RAL-GDS, and TIAM-1, each of which are also subject to activating mutations in cancer (Davies et al., 2002; Samuels and Velculescu, 2004; Philp et al., 2001; Sjöblom et al., 2006; Greenman et al., 2007; Engers et al., 2000).”
BackgroundCooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis
Nogueira, C., Kim, K.-H., Sung, H., Paraiso, K. H. T., Dannenberg, J.-H., Bosenberg, M., Chin, L., & Kim, M. (2010) · Oncogene · doi:10.1038/onc.2010.349 · Cited by 108
“The relevance of RAS-RAF-MAPK pathway in melanoma pathogenesis is evidenced by high frequency BRAF mutations (Davies et al., 2002) and less common yet reciprocal NRAS mutations (Tsao et al., 2004).”
Ferrari de Andrade, L., Ngiow, S. F., Stannard, K., Rusakiewicz, S., Kalimutho, M., Khanna, K. K., Tey, S.-K., Takeda, K., Zitvogel, L., Martinet, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1339 · Cited by 105
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
Botti, G., Fratangelo, F., Cerrone, M., Liguori, G., Cantile, M., Anniciello, A. M., Scala, S., D’Alterio, C., Trimarco, C., Ianaro, A., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1150-7 · Cited by 104
“The full coding sequences and splice junctions of NRAS (exons 1 and 2) and the entire sequence of the BRAF (exon 15) [24, 25] were screened for mutations.”
Self-citationChen, G., Gao, C., Gao, X., Zhang, D. H., Kuan, S.-F., Burns, T. F., & Hu, J. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0561 · Cited by 104
“Although many studies on BRAF inhibitor resistance in colorectal cancer have focused onmechanisms underlying the reactivation of the EGFR/RAS/RAF/MEK/ERK pathway, the current study focuses on identifying novel adaptive signaling mechanisms, a fresh angle on colorectal cancer resistance to BRAF inhibition.”
BackgroundInfluentialFallahi‐Sichani, M., Moerke, N. J., Niepel, M., Zhang, T., Gray, N. S., & Sorger, P. K. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145877 · Cited by 99
“The BRAFV600E oncoprotein constitutively activates pro-mitogenic RAF/MEK/ERK signaling (Davies et al, 2002; Fecher et al, 2008), and therapy with RAF inhibitors such as vemurafenib (Zelboraf ; PLX4032) causes tumor regression in many patients (Bollag et al, 2010; Chapman et al, 2011; Flaherty et…”
Information transfer by leaky, heterogeneous, protein kinase signaling systems
Voliotis, M., Perrett, R. M., McWilliams, C., McArdle, C. A., & Bowsher, C. G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314446111 · Cited by 98
“The B-RAF mutation occurs in the majority of melanomas and results in increased activation of ERK, with the B-RAF single substitution mutation occurring commonly (46).”
BackgroundDisruption of the Rb-Raf-1 Interaction Inhibits Tumor Growth and Angiogenesis
Dasgupta, P., Sun, J., Wang, S., Fusaro, G., Betts, V., Padmanabhan, J., Sebti, S. M., & Chellappan, S. P. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9527-9541.2004 · Cited by 98
“by on February 2, 2010 mcb.asm.org Downloaded from high frequency in melanomas and to a lesser extent in several other human cancers ( 16 ).”
BackgroundINKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases
Beekhof, R., van Alphen, C., Henneman, A. A., Knol, J. C., Pham, T. V., Rolfs, F., Labots, M., Henneberry, E., Le Large, T. Y., de Haas, R. R., et al. (2019) · Molecular Systems Biology · doi:10.15252/msb.20188250 · Cited by 97
Schram, A. M., Gandhi, L., Mita, M. M., Damstrup, L., Campana, F., Hidalgo, M., Grande, E., Hyman, D. M., & Heist, R. S. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0322-4 · Cited by 96
Krumm, A., Barckhausen, C., Kücük, P., Tomaszowski, K.-H., Loquai, C., Fahrer, J., Krämer, O. H., Kaina, B., & Roos, W. P. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2680 · Cited by 91
“29), and they express an oncogenic form of BRAF giving them a growth advantage (46).”
Shapiro, G. I., LoRusso, P., Kwak, E., Pandya, S., Rudin, C. M., Kurkjian, C., Cleary, J. M., Pilat, M. J., Jones, S., de Crespigny, A., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00776-6 · Cited by 90
The specificity of UVA-induced DNA damage in human melanocytes
Mouret, S., Forestier, A., & Douki, T. (2012) · Photochemical & Photobiological Sciences · doi:10.1039/c1pp05185g · Cited by 94
de Keizer, P. L. J., Packer, L. M., Szypowska, A. A., Riedl-Polderman, P. E., van den Broek, N. J. F., de Bruin, A., Dansen, T. B., Marais, R., Brenkman, A. B., & Burgering, B. M. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1563 · Cited by 94
Self-citationMEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity
Duncan, K. E., Chang, L. Y., & Patronas, M. (2015) · Eye · doi:10.1038/eye.2015.82 · Cited by 87
Current targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87
“6%, with the valine-to-glutamic-acid-amino-acid (V600E) substitution being the most common [Davies et al. 2002; Safaee Ardekani et al. 2012].”
BackgroundThe genetics of melanoma: recent advances
Hill, V. K., Gartner, J. J., Samuels, Y., & Goldstein, A. M. (2013) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091212-153429 · Cited by 86
Review Article: The Role of Ras Superfamily Proteins in Bladder Cancer Progression
OXFORD, G., & THEODORESCU, D. (2003) · Journal of Urology · doi:10.1097/01.ju.0000088670.02905.78 · Cited by 86
Shah, M., Stebbins, J. L., Dewing, A., Qi, J., Pellecchia, M., & Ronai, Z. A. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00628.x · Cited by 85
“In melanoma, both the Ras-Raf-MEK-ERK (MAPK) and the hypoxia signaling pathways are activated through multiple mechanisms and play a key role in melanoma development and progression (Bedogni and Powell, 2009; Davies et al., 2002; Meier et al., 2005; Lopez- Bergami et al., 2008).”
BackgroundRecent updates on innovative approaches to overcome drug resistance for better outcomes in cancer
Sharma, M., Bakshi, A. K., Mittapelly, N., Gautam, S., Marwaha, D., Rai, N., Singh, N., Tiwari, P., Agarwal, N., Kumar, A., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.007 · Cited by 84
Maddodi, N., Huang, W., Havighurst, T., Kim, K., Jack Longley, B., & Setaluri, V. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.26 · Cited by 80
“Activating mutations in RAS and the RAS effector BRAF, which activate the mitogen-activated protein kinase (MAPK) signaling pathway, are found in a majority of melanomas (Demunter et al., 2001; Davies et al., 2002; Solit et al., 2006).”
Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies
Montero, J., Gstalder, C., Kim, D. J., Sadowicz, D., Miles, W., Manos, M., Cidado, J. R., Paul Secrist, J., Tron, A. E., Flaherty, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12477-y · Cited by 80
Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies
Pizzimenti, S., Ribero, S., Cucci, M. A., Grattarola, M., Monge, C., Dianzani, C., Barrera, G., & Muzio, G. (2021) · Antioxidants · doi:10.3390/antiox10121942 · Cited by 79
“In particular, in BRAF V600E mutant melanoma, the MAPK activated pathway leads to hyperphosphorylation of FAM129B, which in turn can compete with Nrf2 for the binding to Keap1; in the absence of its inhibitor Keap1, Nrf2 protein is more stable; thus, its level can increase [155].”
BackgroundInfluentialLiang, G., Liu, M., Wang, Q., Shen, Y., Mei, H., Li, D., & Liu, W. (2017) · Oncotarget · doi:10.18632/oncotarget.15324 · Cited by 78
“Activated mutations in the oncogenes B-RAF (the RAS-regulated kinase) and N-RAS have been detected in 50-70% and 15%-30% of melanoma patients, respectively [3].”
BackgroundBenamar, M., Guessous, F., Du, K., Corbett, P., Obeid, J., Gioeli, D., Slingluff, C. L., & Abbas, T. (2016) · eBioMedicine · doi:10.1016/j.ebiom.2016.06.023 · Cited by 77
“%) of cases (Davies et al., 2002; Davies and Samuels, 2010).”
BackgroundThe relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence
Haferkamp, S., Tran, S. L., Becker, T. M., Scurr, L. L., Kefford, R. F., & Rizos, H. (2009) · Aging · doi:10.18632/aging.100051 · Cited by 77
Hugdahl, E., Kalvenes, M. B., Puntervoll, H. E., Ladstein, R. G., & Akslen, L. A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.44 · Cited by 75
Controlling the master—upstream regulation of the tumor suppressor LKB1
Kullmann, L., & Krahn, M. P. (2018) · Oncogene · doi:10.1038/s41388-018-0145-z · Cited by 75
The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
Mauri, G., Bonazzina, E., Amatu, A., Tosi, F., Bencardino, K., Gori, V., Massihnia, D., Cipani, T., Spina, F., Ghezzi, S., et al. (2021) · Cancers · doi:10.3390/cancers13010137 · Cited by 73
“Particularly, BRAF mutations account for 8–10% of mCRCs and more than 90% are missense mutations occurring in codon 600, leading to an aminoacidic substitution of a valine for a glutamic acid (V600E) [6].”
BackgroundProtein–Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway
García-Gómez, R., Bustelo, X. R., & Crespo, P. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.07.002 · Cited by 72
Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter
Redmer, T. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0854-5 · Cited by 67
“The identification of mutations of BRAF in human cancers [125] is a milestone, opened new avenues in the therapy of melanoma and was a prerequisite for the development of small molecule BRAF inhibitors, most important vemurafenib and dabrafenib.”
BackgroundPrognostic Impact of Autophagy Biomarkers for Cutaneous Melanoma
Tang, D. Y. L., Ellis, R. A., & Lovat, P. E. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00236 · Cited by 71
Abdel-Malek, Z. A., Kadekaro, A. L., Kavanagh, R. J., Todorovic, A., Koikov, L. N., Mcnulty, J. C., Jackson, P. J., Millhauser, G. L., Schwemberger, S., Babcock, G., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-5655fje · Cited by 71
“This potential preventive strategy should benefit most individuals with a high risk for melanoma, particularly those heterozygous for melanoma-associated MC1R alleles, or expressing mutations in other melanoma susceptibility genes, such as p16 or BRAF (26, 40 ).”
BackgroundRoda, J. M., Wang, Y., Sumner, L. A., Phillips, G. S., Marsh, C. B., & Eubank, T. D. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103817 · Cited by 71
“60% of patients with malignant melanoma (41) and are present in ∼20% of other malignancies (42).”
BackgroundStructure and function of Gab2 and its role in cancer (Review)
DING, C.-B., YU, W.-N., FENG, J.-H., & LUO, J.-M. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3951 · Cited by 71
“Neuroblastoma v-ras oncogene homolog (NRAS) and v-raf murine sarcoma viral oncogene homolog B1 (BRAF) are oncogenes in melanoma, which are critical for tumor initiation (46).”
López-Cobo, S., Pieper, N., Campos-Silva, C., García-Cuesta, E. M., Reyburn, H. T., Paschen, A., & Valés-Gómez, M. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1392426 · Cited by 71
“Nearly 50% of melanoma lesions have a valine to glutamic acid exchange at position 600 in the BRAF gene, known as BRAF.(4) This mutation leads to constitutive activation of”
BackgroundImpacts of Activation of the Mitogen-Activated Protein Kinase Pathway in Pancreatic Cancer
Furukawa, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00023 · Cited by 70
“Mutations in BRAF commonly involve codon 600 and often result in a V600E substitution, which leads to constitutive activation of its kinase function (8).”
BackgroundBommarito, A., Richiusa, P., Carissimi, E., Pizzolanti, G., Rodolico, V., Zito, G., Criscimanna, A., Di Blasi, F., Pitrone, M., Zerilli, M., et al. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0076 · Cited by 70
“MMPs are tightly regulated by specific inhibitors (tissue inhibitor of metalloproteinases, TIMPs), which control their activation in both physiological and pathological conditions (Sounni & Noel 2005, Deryugina & Quigley 2006).”
BackgroundSchultz, N. A., Roslind, A., Christensen, I. J., Horn, T., Høgdall, E., Pedersen, L. N., Kruhøffer, M., Burcharth, F., Wøjdemann, M., & Johansen, J. S. (2012) · Pancreas · doi:10.1097/mpa.0b013e31823cd9df · Cited by 68
“Except for the V600E mutation, BRAF mutations require interaction with RAS for activation.(18) In patients with colorectal, thyroid, and ovarian adenocarcinomas, KRAS and BRAF mutations are not found together.”
BackgroundBauer, D., Werth, F., Nguyen, H. A., Kiecker, F., & Eberle, J. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.6 · Cited by 68
“changedwith the identification of activating BRAFmutations in about one-half of cutaneous melanomas.(1) Selective BRAF”
BackgroundSex disparities in melanoma outcomes: The role of biology
Nosrati, A., & Wei, M. L. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.06.018 · Cited by 66
Seth, R., Crook, S., Ibrahem, S., Fadhil, W., Jackson, D., & Ilyas, M. (2009) · Gut · doi:10.1136/gut.2008.159137 · Cited by 66
“Approximately 7% of all cancers have been shown to have mutations in BRAF, with A-RAF or C-RAF mutations occurring rarely.(11) 12 The”
BackgroundResultInfluentialWang, B., Zhang, W., Zhang, G., Kwong, L., Lu, H., Tan, J., Sadek, N., Xiao, M., Zhang, J., Labrie, M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01911-5 · Cited by 66
Oncogenic B-RAF Signaling in Melanoma Impairs the Therapeutic Advantage of Autophagy Inhibition
Armstrong, J. L., Corazzari, M., Martin, S., Pagliarini, V., Falasca, L., Hill, D. S., Ellis, N., Al Sabah, S., Redfern, C. P. F., Fimia, G. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3003 · Cited by 65
Equivocal, explicit and emergent actions of PKC isoforms in cancer
Parker, P. J., Brown, S. J., Calleja, V., Chakravarty, P., Cobbaut, M., Linch, M., Marshall, J. J. T., Martini, S., McDonald, N. Q., Soliman, T., et al. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00310-4 · Cited by 65
Lelliott, E. J., McArthur, G. A., Oliaro, J., & Sheppard, K. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661737 · Cited by 65
“This mutation occurs at codon 600, resulting in substitution of a valine (V) residue, often with a glutamate (E), which renders the kinase constitutively active (22 – 24).”
BackgroundShinozaki, E., Yoshino, T., Yamazaki, K., Muro, K., Yamaguchi, K., Nishina, T., Yuki, S., Shitara, K., Bando, H., Mimaki, S., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.308 · Cited by 65
“…BRAF mutations in CRC is substitution from valine to glutamic acid at codon 600 (V600E), located in exon 15, leading to 130- to 700-fold increased BRAF kinase activity compared with that of wild-type BRAF; these mutations are reported in B5–12% of cases (Davies et al, 2002; Andreadi et al, 2012).”
Ocular toxicity due to Trametinib and Dabrafenib
Sarny, S., Neumayer, M., Kofler, J., & El-Shabrawi, Y. (2017) · BMC Ophthalmology · doi:10.1186/s12886-017-0541-0 · Cited by 61
“Of the melanomas 80–90% show a mutation in BRAF V600E and 10–20% in BRAF V600 K [1].”
PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF -Mutated Melanoma
Deuker, M. M., Marsh Durban, V., Phillips, W. A., & McMahon, M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0856 · Cited by 60
“Approximately 50% of melanomas express mutationally activated BRAF, leading to constitutive activation of the BRAF MEK1/2 ERK1/2 mitogen-activated protein (MAP) kinase pathway (3).”
Sale, M. J., & Cook, S. J. (2013) · Biochemical Journal · doi:10.1042/bj20121212 · Cited by 58
Puig-Butille, J. A., Vinyals, A., Ferreres, J. R., Aguilera, P., Cabré, E., Tell-Martí, G., Marcoval, J., Mateo, F., Palomero, L., Badenas, C., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.01.021 · Cited by 58
Jauhri, M., Bhatnagar, A., Gupta, S., BP, M., Minhas, S., Shokeen, Y., & Aggarwal, S. (2017) · Tumor Biology · doi:10.1177/1010428317692265 · Cited by 57
Metadata
- Authors
- Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W. C., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., & Futreal, P. A.
- Affiliations
- Wellcome Sanger Institute (GB)
- Institute of Cancer Research (GB)
- Western Infirmary (GB)
- University of York (GB)
- Duke University (US)
- National Research Council (IT)
- University of Sassari (IT)
- Royal Brompton Hospital (GB)
- Queen Mary Hospital (CN)
- Abramson Cancer Center (US)
- Corresponding author
- Wooster, Richard
- ORCID
- Davies, Helen
- Edkins, Sarah
- Teague, Jon
- Garnett, Mathew J.
- Dicks, Ed
- Gray, Kristian
- Hughes, Jaime
- Kosmidou, Vivian
- Menzies, Andrew
- Watt, Stephen
- Hooper, Steven
- Shipley, Janet
- Hargrave, Darren
- Maitland, Norman
- Riggins, Gregory J.
- Bigner, Darell D.
- Palmieri, Giuseppe
- Cossu, Antonio
- Flanagan, Adrienne
- Nicholson, Andrew
- Ho, Judy W. C.
- Yuen, Siu T.
- Paterson, Hugh
- Marais, Richard
- Stratton, Michael R.
- Futreal, P. Andrew
- Venue
- Nature
- Published
- 2002-06
- Volume
- 417
- Issue
- 6892
- Pages
- 949-954
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2163188200
- Cited by
- 10,674
- References
- 24
- Citations by year
- 2026: 221 · 2025: 282 · 2024: 435 · 2023: 450 · 2022: 442 · 2021: 506 · 2020: 538 · 2019: 482 · 2018: 519 · 2017: 576 · 2016: 576 · 2015: 649 · 2014: 701 · 2013: 688 · 2012: 563
- FWCI
- 87.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- BRAF mutation, somatic missense mutations, melanoma, oncogenic Ras, kinase activity, malignant transformation, therapeutic target
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Cell Division, Cell Transformation, Neoplastic, DNA Mutational Analysis, Enzyme Activation, Humans, Melanoma, Molecular Sequence Data, Neoplasms, Tumor Cells, Cultured, 3T3 Cells, Protein Structure, Tertiary, ras Proteins, Proto-Oncogene Proteins c-raf, Mutation, Missense, Mitogen-Activated Protein Kinases, MAP Kinase Signaling System, Proto-Oncogene Proteins B-raf, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.